U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561983) titled 'Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC' on April 24.
Brief Summary: The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:
* What is the 1-year event-free survival (EFS) rate with this treatment?
* Can this treatment improve tumor response and the chance of curative-intent resection?
* What adverse events occur during treatment?
Participan...